Status: Recruiting
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL
Participants needed: 30
Trial details
Phase: Phase 1, Phase 2Age: 3-70Biological sex: AllType: InterventionalSponsor: Peking University People's HospitalUpdated: May 7, 2026Locations: 1
Eligibility criteria
The subject or guardian understands and voluntarily signs the informed consent f... [+13]
Epilepsy [+45]